Unity Biotechnology

What it is

Unity Biotechnology was founded in 2011 by Judith Campisi, Nathaniel David, and others as the first dedicated senolytic company. IPO’d in 2018 with significant attention; subsequently restructured following unexpected disappointments in early systemic senolytic trials.

Pivot

The original osteoarthritis-knee programme (UBX0101) failed in Phase 2. Unity pivoted to intravitreal (eye-injected) senolytics for diabetic macular edema and neovascular AMD:

• UBX1325 (foselutoclax) — a BCL-xL inhibitor delivered locally to the retina, where systemic toxicity is avoided.
• Phase 2 results showed visual-acuity improvements with extended durability, encouraging further development.

Why it matters

• Validates the principle that local senolytic delivery can sidestep the haematological toxicity of BCL-family inhibitors that limits systemic dosing.
• Demonstrates the long, hard road from senescence biology to clinically useful medicine, in contrast to over-promising consumer narratives.

Historical significance

Unity Biotechnology, co-founded by Nathaniel David, Judith Campisi, and Jan van Deursen in 2011 and IPO'd in 2018, was the field's first major public-market longevity biotech. Its early trajectory was closely watched as a bellwether for whether the geroscience thesis could sustain public-market investor appetite.

Programme evolution

• UBX0101 (osteoarthritis): Phase 2 failure in 2020 was a significant setback and drove strategic pivots.
• UBX1325 (age-related macular degeneration, diabetic macular oedema): the current lead asset; intravitreal senolytic showing early efficacy signals.
• Follow-on candidates in ophthalmology remain the primary focus.

What it teaches the field

Unity's story illustrates the challenges of first-in-class senolytic development: translating rodent-model efficacy to human clinical endpoints has been harder than initial optimism suggested. The company's persistence in ophthalmology reflects both the tractable local delivery and the clearer patient benefit signal in specific diseases.

Related entries

Senolytics, Judith Campisi, Cellular senescence.

More on this topic

• Stealth BioTherapeutics — Company.
• Rapamycin vs Senolytics — Comparison.
• Zinc — Intervention.
• James Kirkland — Researcher.

Related entries

Cellular senescence, Senolytics, Age-related macular degeneration, Judith Campisi.